At the news
? NEUTRALIMPACT 2/10 3 filed Nov 12, 2026 at 16:01 ET
Multiple Form 3 filings were submitted by officers, directors, and a major stockholder of InMed Pharmaceuticals Inc. (now Mentari Therapeutics) following a merger effective November 6, 2026. The filings disclose insider equity holdings and a significant stake by Fairmount Healthcare Fund II L.P., which received over 10.5 million common shares, 4,013 shares of Series A Non-Voting Preferred Stock convertible into 4,013,000 common shares, and pre-funded warrants for 1,468,222 common shares in the merger. The filings are routine post-merger ownership disclosures and do not contain any material financial data or guidance.
- Effective November 6, 2026, InMed Pharmaceuticals Inc. completed a merger with Mentari Therapeutics Inc., with the issuer renamed Mentari Therapeutics Inc.
- Brett Hagen (SVP, Finance and CAO) received options to purchase 62,273 shares at $10.37 per share, vesting over 4 years.
- Jerad G. Seurer (General Counsel and Corporate Secretary) received options to purchase 93,411 shares at $10.37 per share, vesting over 4 years.
- Fairmount Healthcare Fund II L.P. received 10,555,507 common shares, 4,013 shares of Series A Non-Voting Preferred Stock (convertible into 4,013,000 common shares), and pre-funded warrants for 1,468,222 common shares in the merger.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access